Full TitleA Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called “castration-resistant prostate cancers” (CRPC).
The purpose of this study is to assess the safety and effectiveness of the investigational drug ceralasertib to treat patients with metastatic CRPC or other solid tumors containing a molecular change in a protein called ATM. Ceralasterib works by damaging the DNA of cancer cells. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic CRPC or an advanced solid tumor that cannot be successfully treated with standard therapies.
- Patients’ tumors must contain mutated ATM.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Wassim Abida at 646-422-4633.